Starpharma Holdings Ltd - Asset Resilience Ratio

Latest as of December 2025: 69.74%

Starpharma Holdings Ltd (SPL) has an Asset Resilience Ratio of 69.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Starpharma Holdings Ltd (SPL) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$18.25 Million
≈ $12.91 Million USD Cash + Short-term Investments

Total Assets

AU$26.17 Million
≈ $18.51 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Starpharma Holdings Ltd's Asset Resilience Ratio has changed over time. See SPL equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Starpharma Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Starpharma Holdings Ltd (SPL) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$18.25 Million 69.74%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$18.25 Million 69.74%

Asset Resilience Insights

  • Very High Liquidity: Starpharma Holdings Ltd maintains exceptional liquid asset reserves at 69.74% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Starpharma Holdings Ltd Industry Peers by Asset Resilience Ratio

Compare Starpharma Holdings Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revolution Medicines Inc
NASDAQ:RVMD
Biotechnology 65.10%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Hugel Inc
KQ:145020
Biotechnology 29.57%
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Biotechnology 39.07%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Absci Corp
NASDAQ:ABSI
Biotechnology 59.86%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%
Lifecome Biochemistry Co Ltd
SHE:002868
Biotechnology 4.69%

Annual Asset Resilience Ratio for Starpharma Holdings Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Starpharma Holdings Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 59.40% AU$15.10 Million
≈ $10.68 Million
AU$25.42 Million
≈ $17.99 Million
-2.61pp
2024-06-30 62.01% AU$22.83 Million
≈ $16.15 Million
AU$36.81 Million
≈ $26.05 Million
-2.34pp
2023-06-30 64.35% AU$33.52 Million
≈ $23.72 Million
AU$52.09 Million
≈ $36.85 Million
-4.85pp
2022-06-30 69.20% AU$45.79 Million
≈ $32.40 Million
AU$66.17 Million
≈ $46.82 Million
-9.04pp
2021-06-30 78.24% AU$57.30 Million
≈ $40.54 Million
AU$73.24 Million
≈ $51.82 Million
+11.74pp
2020-06-30 66.49% AU$25.98 Million
≈ $18.39 Million
AU$39.08 Million
≈ $27.65 Million
-11.91pp
2019-06-30 78.40% AU$38.31 Million
≈ $27.10 Million
AU$48.86 Million
≈ $34.57 Million
-3.58pp
2018-06-30 81.98% AU$47.97 Million
≈ $33.94 Million
AU$58.51 Million
≈ $41.40 Million
-4.88pp
2017-06-30 86.85% AU$57.84 Million
≈ $40.92 Million
AU$66.59 Million
≈ $47.12 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$59.04 Million
≈ $41.77 Million
--
pp = percentage points

About Starpharma Holdings Ltd

AU:SPL Australia Biotechnology
Market Cap
$206.99 Million
AU$292.55 Million AUD
Market Cap Rank
#16492 Global
#463 in Australia
Share Price
AU$0.70
Change (1 day)
-0.71%
52-Week Range
AU$0.09 - AU$0.76
All Time High
AU$2.49
About

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more